Drug intelligence / Profile preview

Rveiling PDRN

Development stage: Unknown
Lead developer: Aowita
Administration: Topical

Overview

Rveiling PDRN is a topical anti-aging repair serum developed by Aowita Biotech. The product contains polydeoxyribonucleotide (PDRN), a mixture of deoxyribonucleotides derived from salmon sperm DNA. PDRN functions primarily as an agonist of the adenosine A2A receptor, which triggers a cascade of intracellular signaling that promotes tissue regeneration, increases fibroblast metabolic activity, and stimulates the synthesis of collagen and elastin. These biological actions help to repair damaged skin, improve elasticity, and reduce the clinical signs of aging. Although PDRN is used in pharmaceutical contexts for wound healing, Rveiling PDRN is positioned as a high-end cosmetic skincare product.

Brand names: Rveiling PDRNPDRN Skin Anti-Aging Repair Serum
Other names: PDRN Skin Anti-Aging Repair Serum

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on Rveiling PDRN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rveiling PDRN.

Explore the full profile